A Personalized 14-3-3 Disease-Targeting Workflow Yields Repositioning Drug Candidates
Cells · 2025
DOI: 10.3390/cells14080559 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Yonika A Larasati und 4 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research Center in Oncohaematology, Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, CH-1211 Ge…. Hauptthemen laut MEDLINE: 14-3-3 Proteins, Drug Repositioning, Precision Medicine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation Privée des HUG, Fondation de l'Hôpital de La Tour, Aga Khan Foundation.
Abstract (Originalsprache)
Rare diseases typically evade the application of the standard drug discovery and development pipelines due to their understudied molecular etiology and the small market size. Herein, we report a rare disease-directed workflow that rapidly studies the molecular features of the disorder, establishes a high-throughput screening (HTS) platform, and conducts an HTS of thousands of approved drugs to identify and validate repositioning drug candidates. This study examines the pediatric neurological disorder caused by de novo mutations in YWHAG, the gene encoding the scaffolding protein 14-3-3γ, and the workflow discovers nuclear relocalization and a severe drop in 14-3-3γ binding to its phosphorylated protein partners as the key molecular features of the pathogenic hotspot YWHAG mutations. We further established a robust in vitro HTS platform and screened ca. 3000 approved drugs to identify the repositioning drug candidates that restore the deficient 14-3-3γ-phosphotarget interactions. Our workflow can be applied to other 14-3-3-related disorders and upscaled for many other rare diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Research Center in Oncohaematology, Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, CH-1211 Geneva, Switzerland.
- Pediatric Neurology Unit, University Hospitals of Geneva, CH-1211 Geneva, Switzerland.
- Translational Oncology Research Center, Qatar Biomedical Research Institute (QBRI), College of Health and Life Sciences, Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha P.O. Box 34110, Qatar.
ORCID-Profile: Yonika A Larasati, Gonzalo P Solis, Christian Korff, Vladimir L Katanaev
Förderung
- Fondation Privée des HUG
- Fondation de l'Hôpital de La Tour
- Aga Khan Foundation
- Fondation de l’Hôpital de La Tour
Zitieren
APA
Larasati, Y. A., Solis, G. P., Koval, A., Korff, C., & Katanaev, V. L. (2025). A Personalized 14-3-3 Disease-Targeting Workflow Yields Repositioning Drug Candidates. Cells. https://doi.org/10.3390/cells14080559
Vancouver
Larasati YA, Solis GP, Koval A, Korff C, Katanaev VL. A Personalized 14-3-3 Disease-Targeting Workflow Yields Repositioning Drug Candidates. Cells. 2025. doi:10.3390/cells14080559
BibTeX
@article{Larasati2025,
author = {Larasati, Yonika A and Solis, Gonzalo P and Koval, Alexey and Korff, Christian and Katanaev, Vladimir L},
title = {A Personalized 14-3-3 Disease-Targeting Workflow Yields Repositioning Drug Candidates},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14080559}
}
EUVIMED